Summit Therapeutics (SMMT) Expected to Announce Quarterly Earnings on Thursday

Summit Therapeutics (NASDAQ:SMMT) is anticipated to issue its Q2 2026 results after the market closes on Thursday, July 23rd. Analysts expect the company to post earnings of ($0.26) per share and revenue of $0.1090 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 23, 2026 at 4:30 PM ET.

Summit Therapeutics (NASDAQ:SMMT) last posted its earnings results on Friday, May 1st. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.03. On average, analysts expect Summit Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Summit Therapeutics Stock Down 2.2%

Shares of Summit Therapeutics stock opened at $13.50 on Tuesday. The stock has a market capitalization of $10.48 billion, a P/E ratio of -8.44 and a beta of -1.26. The company has a 50-day simple moving average of $15.32 and a 200 day simple moving average of $16.76. Summit Therapeutics has a 12-month low of $12.55 and a 12-month high of $30.98.

Wall Street Analysts Forecast Growth

SMMT has been the topic of several research analyst reports. Truist Financial raised shares of Summit Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Summit Therapeutics in a research note on Friday, May 22nd. Stifel Nicolaus initiated coverage on Summit Therapeutics in a report on Wednesday, April 8th. They issued a “buy” rating and a $45.00 target price on the stock. Piper Sandler decreased their price target on Summit Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research report on Friday, May 1st. Finally, Sanford C. Bernstein started coverage on Summit Therapeutics in a research report on Thursday, May 21st. They set an “underperform” rating and a $7.70 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $26.97.

Insider Buying and Selling

In related news, CEO Robert W. Duggan bought 3,810,000 shares of the company’s stock in a transaction on Friday, June 12th. The stock was bought at an average cost of $13.12 per share, with a total value of $49,987,200.00. Following the completion of the purchase, the chief executive officer owned 573,883,879 shares in the company, valued at approximately $7,529,356,492.48. The trade was a 0.67% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Manmeet Singh Soni bought 50,000 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was bought at an average cost of $14.45 per share, with a total value of $722,500.00. Following the completion of the purchase, the chief financial officer owned 3,123,603 shares of the company’s stock, valued at approximately $45,136,063.35. The trade was a 1.63% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 7,870,000 shares of company stock worth $103,616,900 in the last 90 days. Corporate insiders own 83.50% of the company’s stock.

Institutional Trading of Summit Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC lifted its holdings in Summit Therapeutics by 5.0% during the 1st quarter. AQR Capital Management LLC now owns 65,623 shares of the company’s stock worth $1,266,000 after buying an additional 3,134 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Summit Therapeutics by 1.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 65,411 shares of the company’s stock valued at $1,273,000 after buying an additional 694 shares during the period. Creative Planning raised its position in shares of Summit Therapeutics by 6.7% during the second quarter. Creative Planning now owns 21,390 shares of the company’s stock worth $455,000 after acquiring an additional 1,336 shares during the last quarter. Legal & General Group Plc raised its position in shares of Summit Therapeutics by 33.8% during the second quarter. Legal & General Group Plc now owns 26,367 shares of the company’s stock worth $561,000 after acquiring an additional 6,662 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of Summit Therapeutics during the second quarter worth $132,000. Institutional investors and hedge funds own 4.61% of the company’s stock.

Summit Therapeutics Company Profile

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.